Patients who are at low risk for pulmonary embolism can be safely assessed with clinical criteria.
Computed tomography pulmonary angiography may not be needed to rule out suspected pulmonary embolism (PE) among low-risk patients, according to a study published in JAMA.
Researchers from France performed a crossover cluster–randomized clinical noninferiority trial to validate the safety of the pulmonary embolism rule-out criteria (PERC), an 8-item block of clinical criteria, compared with conventional assessments which include CT pulmonary angiography.
A total of 1,916 patients with a low gestalt clinical probability of PE were cluster-randomized for the trial; 962 were assigned to the PERC group and 954 were assigned to the control group. The subjects’ mean age was 44 years and 980 were women (51 percent); 1,749 patients completed the trial. The primary end point was the occurrence of a thromboembolic event during the three-month follow-up period that was not initially diagnosed and secondary end points included the rate of computed tomographic pulmonary angiography (CTPA), median length of stay in the emergency department, and rate of hospital admission.
The results showed PE was diagnosed at initial presentation in 26 patients in the control group (2.7 percent) compared with 14 (1.5 percent) in the PERC group. One PE (0.1 percent) was diagnosed during follow-up in the PERC group compared with none in the control group. The proportion of patients undergoing CTPA in the PERC group versus the control group was 13 percent versus 23 percent. In the PERC group, rates were significantly reduced for the median length of emergency department stay (mean reduction, 36 minutes) and hospital admission.
The researchers concluded that PERC was a safe approach for very low-risk patients with suspected PE, and compared with conventional strategy, PERC did not result in an inferior rate of thromboembolic events over three months.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.